PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23013513-0 2013 Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Simvastatin 11-22 C-reactive protein Homo sapiens 75-93 23159435-4 2013 RESULTS: Simvastatin, but not placebo, reduced monocyte release of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta and monocyte chemoattractant protein-1, as well decreased plasma levels of C-reactive protein. Simvastatin 9-20 C-reactive protein Homo sapiens 204-222 23950601-4 2013 RESULTS: Ninety-day simvastatin treatment reduced lymphocyte release of TNF-alpha, interleukin-2 and interferon-gamma, which was accompanied by a decrease in plasma C-reactive protein. Simvastatin 20-31 C-reactive protein Homo sapiens 165-183 23107042-5 2012 Metformin, but not placebo, administered to simvastatin-treated IFG subjects reduced plasma levels of C-reactive protein, soluble intercellular adhesion molecule-1, as well as lymphocyte release of interleukin-2, interferon-gamma and tumor necrosis factor-alpha, which was accompanied by the improvement in insulin sensitivity and a reduction in free fatty acid levels. Simvastatin 44-55 C-reactive protein Homo sapiens 102-120 21913974-4 2012 Concomitantly, repeated administration of simvastatin, ramipril or simvastatin in combination with ramipril to these animals, increased nitric oxide (NO) production and decreased the elevated serum malondialdehyde (MDA) and high sensitivity C-reactive protein (hs-CRP) levels. Simvastatin 42-53 C-reactive protein Homo sapiens 241-259 21913974-4 2012 Concomitantly, repeated administration of simvastatin, ramipril or simvastatin in combination with ramipril to these animals, increased nitric oxide (NO) production and decreased the elevated serum malondialdehyde (MDA) and high sensitivity C-reactive protein (hs-CRP) levels. Simvastatin 67-78 C-reactive protein Homo sapiens 241-259 20678906-7 2012 Simvastatin use was associated with significant reductions in total cholesterol, LDL, ox-LDL and CRP. Simvastatin 0-11 C-reactive protein Homo sapiens 97-100 22950641-5 2012 Simvastatin resulted in a significant decrease in CRP, which correlated with decreases in both total (r = 0.87, p < 0.05) and low-density lipoprotein cholesterol, IL-6, sICAM-1, sVCAM-1, oxLDL, and sFas at 6 months, compared to baseline. Simvastatin 0-11 C-reactive protein Homo sapiens 50-53 21477202-10 2011 Our preliminary findings showing a dose-related effect of simvastatin on levels of NOx, CRP and IL-6 suggest a potential therapeutic role for simvastatin in SCD. Simvastatin 58-69 C-reactive protein Homo sapiens 88-91 20607595-4 2011 Simvastatin treatment significantly reduced C-reactive protein (CRP) levels while interleukin (IL)-6 levels remained unchanged. Simvastatin 0-11 C-reactive protein Homo sapiens 44-62 20607595-4 2011 Simvastatin treatment significantly reduced C-reactive protein (CRP) levels while interleukin (IL)-6 levels remained unchanged. Simvastatin 0-11 C-reactive protein Homo sapiens 64-67 21865358-9 2011 Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1. Simvastatin 5-16 C-reactive protein Homo sapiens 124-142 22027793-4 2011 RESULTS: At the end of 12 months, the patients in simvastatin group showed significantly reduced total cholesterol, LDL-C, CRP, TNF-alpha, and (99)Tc(m)-MIBI uptake fraction. Simvastatin 50-61 C-reactive protein Homo sapiens 123-126 20445760-9 2010 There was no overlap of lipids whose changes correlated with LDL-C or CRP responses to simvastatin suggesting that distinct metabolic pathways govern statin effects on these two biomarkers. Simvastatin 87-98 C-reactive protein Homo sapiens 70-73 21276586-5 2011 Simvastatin and fenofibrate decreased monocyte release of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1 and lymphocyte release of interleukin-2, interferon-gamma, and tumor necrosis factor-alpha, which was accompanied by a decrease in plasma C-reactive protein levels. Simvastatin 0-11 C-reactive protein Homo sapiens 298-316 21181364-14 2010 Simvastatin administration can significantly inhibit the DCs function and reduce the level of hs-CRP, indicating the suppression on inflammatory reaction may be one of the mechanisms by which simvastatin exerts its effect in treating RA. Simvastatin 0-11 C-reactive protein Homo sapiens 97-100 21181364-14 2010 Simvastatin administration can significantly inhibit the DCs function and reduce the level of hs-CRP, indicating the suppression on inflammatory reaction may be one of the mechanisms by which simvastatin exerts its effect in treating RA. Simvastatin 192-203 C-reactive protein Homo sapiens 97-100 20084446-2 2010 The present study aims to describe the profile of the simvastatin users and non-users in relation to FRS and high-sensitivity CRP (hs-CRP) levels. Simvastatin 54-65 C-reactive protein Homo sapiens 126-129 20084446-2 2010 The present study aims to describe the profile of the simvastatin users and non-users in relation to FRS and high-sensitivity CRP (hs-CRP) levels. Simvastatin 54-65 C-reactive protein Homo sapiens 134-137 20676836-5 2010 In both groups studied, simvastatin significantly improved lipids, and reduced C-reactive protein and fibrinogen levels. Simvastatin 24-35 C-reactive protein Homo sapiens 79-97 19694216-8 2009 RESULTS: Simvastatin led to a significant decrease in total cholesterol, LDL cholesterol, triglycerides and C-reactive protein (CRP), while fibrinogen levels remained unaltered. Simvastatin 9-20 C-reactive protein Homo sapiens 108-126 20150839-12 2010 There was a nonsignificant reduction of CRP and IL-6 in the subgroup with FEV1 >50% during simvastatin treatment. Simvastatin 94-105 C-reactive protein Homo sapiens 40-43 19694216-8 2009 RESULTS: Simvastatin led to a significant decrease in total cholesterol, LDL cholesterol, triglycerides and C-reactive protein (CRP), while fibrinogen levels remained unaltered. Simvastatin 9-20 C-reactive protein Homo sapiens 128-131 19694216-10 2009 These changes were correlated with reduction in CRP following simvastatin. Simvastatin 62-73 C-reactive protein Homo sapiens 48-51 19694216-11 2009 Simvastatin-induced increase in clot permeability was associated only with age and decrease in CRP levels (R2 for the model = 0.61), while shortening of clot lysis time observed following simvastatin use was predicted only by reduction of triglycerides and CRP (R2 for the model = 0.62). Simvastatin 0-11 C-reactive protein Homo sapiens 95-98 19694216-11 2009 Simvastatin-induced increase in clot permeability was associated only with age and decrease in CRP levels (R2 for the model = 0.61), while shortening of clot lysis time observed following simvastatin use was predicted only by reduction of triglycerides and CRP (R2 for the model = 0.62). Simvastatin 0-11 C-reactive protein Homo sapiens 257-260 20440247-8 2010 RESULTS: Five months of simvastatin treatment showed a decrease in lipid levels, concomitantly with reduction in PMNL priming, PMNL apoptosis, fibrinogen and CRP levels. Simvastatin 24-35 C-reactive protein Homo sapiens 158-161 20142117-0 2010 Efficacy of simvastatin or ezetimibe on tissue factor, von Willebrand"s factor and C-reactive protein in patients with hypercholesterolaemia. Simvastatin 12-23 C-reactive protein Homo sapiens 83-101 19555253-6 2009 Plasminogen activator inhibitor-1 (PAI-1) and high-sensitivity C reactive protein (hs-CRP) decreased after 12 months compared to baseline with simvastatin, and with fenofibrate + simvastatin even if the value obtained with fenofibrate-simvastatin was the lowest. Simvastatin 143-154 C-reactive protein Homo sapiens 63-81 19324974-8 2009 MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). Simvastatin 49-60 C-reactive protein Homo sapiens 189-207 19324974-8 2009 MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). Simvastatin 49-60 C-reactive protein Homo sapiens 209-212 19324974-8 2009 MEASUREMENTS AND MAIN RESULTS: Pretreatment with simvastatin reduced LPS-induced BALF neutrophilia, myeloperoxidase, tumor necrosis factor-alpha, matrix metalloproteinases 7, 8, and 9, and C-reactive protein (CRP) as well as plasma CRP (all P < 0.05 vs. placebo). Simvastatin 49-60 C-reactive protein Homo sapiens 232-235 19151033-7 2009 RESULTS: Treatment with simvastatin or atorvastatin decreased CRP-induced release of CCL2, CCL3 and CCL4. Simvastatin 24-35 C-reactive protein Homo sapiens 62-65 19301201-7 2009 Simvastatin significantly reduced CRP by 26%, whereas IL-6 remained unchanged. Simvastatin 0-11 C-reactive protein Homo sapiens 34-37 19151033-9 2009 Treatments with 1 microM simvastatin or atorvastatin significantly inhibited monocyte migration in response to CRP. Simvastatin 25-36 C-reactive protein Homo sapiens 111-114 18057884-2 2008 We tested the hypothesis that simvastatin inhibited CRP-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Simvastatin 30-41 C-reactive protein Homo sapiens 52-55 19195502-0 2009 Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction. Simvastatin 65-76 C-reactive protein Homo sapiens 89-107 18855257-8 2008 Hydrophilic pravastatin increased the serum adiponectin level and decreased the CRP after switching from lipophilic simvastatin in the absence of any difference in the low-density lipoprotein cholesterol level and blood pressure. Simvastatin 116-127 C-reactive protein Homo sapiens 80-83 18057884-0 2008 Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Simvastatin 0-11 C-reactive protein Homo sapiens 21-39 18264935-6 2008 As expected, simvastatin caused significant reductions in total cholesterol, LDL cholesterol and triglycerides, as well as in C-reactive protein (CRP; -28%, p=0.001) and IL-6 (-20%, p=0.05) but failed to decrease plasma ADMA both in crude and adjusted analyses. Simvastatin 13-24 C-reactive protein Homo sapiens 126-144 18264935-6 2008 As expected, simvastatin caused significant reductions in total cholesterol, LDL cholesterol and triglycerides, as well as in C-reactive protein (CRP; -28%, p=0.001) and IL-6 (-20%, p=0.05) but failed to decrease plasma ADMA both in crude and adjusted analyses. Simvastatin 13-24 C-reactive protein Homo sapiens 146-149 18023360-0 2007 Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. Simvastatin 79-90 C-reactive protein Homo sapiens 10-28 18023360-5 2007 PURPOSE: The aim of the present study, therefore, was to assess the effects of both CRP on resistin expression and simvastatin on CRP-induced of resistin expression in cultured human PBMC. Simvastatin 115-126 C-reactive protein Homo sapiens 130-133 18023360-12 2007 Co-incubation with simvastatin significantly inhibited CRP-induced up-regulation of mRNA and protein expression of resistin. Simvastatin 19-30 C-reactive protein Homo sapiens 55-58 18023360-14 2007 CONCLUSIONS: In the present study, the data showed that CRP could significantly increase resistin expression in cultured human PBMC, and this effect was inhibited by simvastatin, suggesting that CRP and resistin might be involved in the pathogenesis of atherosclerosis, and statin therapy might be beneficial for atherosclerotic disease by modifying CRP-induced resistin overexpression in PBMC. Simvastatin 166-177 C-reactive protein Homo sapiens 56-59 18023360-14 2007 CONCLUSIONS: In the present study, the data showed that CRP could significantly increase resistin expression in cultured human PBMC, and this effect was inhibited by simvastatin, suggesting that CRP and resistin might be involved in the pathogenesis of atherosclerosis, and statin therapy might be beneficial for atherosclerotic disease by modifying CRP-induced resistin overexpression in PBMC. Simvastatin 166-177 C-reactive protein Homo sapiens 195-198 18023360-14 2007 CONCLUSIONS: In the present study, the data showed that CRP could significantly increase resistin expression in cultured human PBMC, and this effect was inhibited by simvastatin, suggesting that CRP and resistin might be involved in the pathogenesis of atherosclerosis, and statin therapy might be beneficial for atherosclerotic disease by modifying CRP-induced resistin overexpression in PBMC. Simvastatin 166-177 C-reactive protein Homo sapiens 195-198 18057884-5 2008 RESULTS: Pre-treatment with simvastatin significantly attenuated the CRP-induced CD32 expression and NF-kappaB activation in human umbilical vein endothelial cells. Simvastatin 28-39 C-reactive protein Homo sapiens 69-72 18057884-6 2008 Simvastatin also decreased CRP-induced vascular cell adhesion molecule-1 expression and reduced monocyte adhesion on endothelial cells. Simvastatin 0-11 C-reactive protein Homo sapiens 27-30 18057884-10 2008 CONCLUSIONS: CRP-induced CD32 expression and NF-kappaB activation were attenuated by simvastatin. Simvastatin 85-96 C-reactive protein Homo sapiens 13-16 16860807-5 2007 The serum levels of C-reactive protein (CRP) were significantly reduced by simvastatin. Simvastatin 75-86 C-reactive protein Homo sapiens 20-38 17719471-6 2007 RESULTS: Both ezetimibe and simvastatin significantly reduced total cholesterol (-0.62 +/- 0.55 mmol/l and -1.28 +/- 0.49 mmol/l, respectively; p < 0.001), low-density lipoprotein cholesterol (-0.55 +/- 0.55 mmol/l and -1.28 +/- 0.49 mmol/l; p < 0.0001), and C-reactive protein (-5.35 +/- 9.25 mg/l and -5.05 +/- 6.30 mg/l; p < 0.001). Simvastatin 28-39 C-reactive protein Homo sapiens 265-283 17196684-1 2007 BACKGROUND: We hypothesize that high-sensitivity C-reactive protein (hs-CRP) levels and cell adhesion molecules (CAMs) significantly reflect serial changes in patients with atherosclerotic-risk factors undergoing simvastatin therapy. Simvastatin 213-224 C-reactive protein Homo sapiens 72-75 17196684-2 2007 We further hypothesize that the site specificity of CRP on the expression of CAMs, which can be inhibited by simvastatin, is in the cytoplasm of endothelial cells (EC). Simvastatin 109-120 C-reactive protein Homo sapiens 52-55 17196684-9 2007 After simvastatin therapy was withdrawn, the hs-CRP level was once again significantly higher on day 270 than on day 180 (p<0.05), but VCAM-1 did not differ between day 180 and day 270. Simvastatin 6-17 C-reactive protein Homo sapiens 48-51 17196684-10 2007 25 micromol/L simvastatin markedly suppressed the CRP effect on VCAM-1 and intercellular CAM-1 expressions of EC. Simvastatin 14-25 C-reactive protein Homo sapiens 50-53 17196684-12 2007 However, pretreatment with simvastatin reduced the intensity of CRP in cytoplasm. Simvastatin 27-38 C-reactive protein Homo sapiens 64-67 17196684-13 2007 CONCLUSIONS: CRP-mediated inflammation is inhibited by simvastatin. Simvastatin 55-66 C-reactive protein Homo sapiens 13-16 16860807-5 2007 The serum levels of C-reactive protein (CRP) were significantly reduced by simvastatin. Simvastatin 75-86 C-reactive protein Homo sapiens 40-43 17145229-0 2006 Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus. Simvastatin 49-60 C-reactive protein Homo sapiens 15-33 18219956-0 2007 [The effects of early application of simvastatin on C-reactive protein level, blood lipids, and the clinical course of acute coronary syndrome]. Simvastatin 37-48 C-reactive protein Homo sapiens 52-70 18219956-6 2007 Mean CRP level decreased significantly within two weeks in the group of patients receiving simvastatin (from 14.9 +/- 9.7 to 7.6 +/- 6.0 mg/l; p = 0.02). Simvastatin 91-102 C-reactive protein Homo sapiens 5-8 17929126-8 2007 Of special interest was that the median levels of erythrocytes sedimentation rate, C-reactive protein, and rheumatoid factor were significantly decreased from 54.0 mm/h to 45.5 mm/h, from 1.50 mg/dl to 0.85 mg/dl, and from 57.0 IU/ml to 28.0 IU/ml, respectively, after administration of simvastatin. Simvastatin 287-298 C-reactive protein Homo sapiens 83-124 17560879-0 2007 Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Simvastatin 35-46 C-reactive protein Homo sapiens 98-116 17560879-0 2007 Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Simvastatin 54-65 C-reactive protein Homo sapiens 98-116 17560879-3 2007 When averaged across doses, ezetimibe/simvastatin produced significantly greater reductions compared with simvastatin alone in LDL cholesterol (52.5% vs 38.0%, respectively) and CRP levels (31.0% vs 14.3%, respectively). Simvastatin 38-49 C-reactive protein Homo sapiens 178-181 17560879-6 2007 Reductions in CRP of similar magnitude were observed with ezetimibe/simvastatin and atorvastatin when averaged across doses and at each milligram-equivalent statin dose comparison. Simvastatin 68-79 C-reactive protein Homo sapiens 14-17 16999946-0 2007 Reduction of C-reactive protein by a single 80 mg of simvastatin in patients with unstable angina. Simvastatin 53-64 C-reactive protein Homo sapiens 13-31 16999946-2 2007 Limited information has been available, however, with respect to evaluating a potential effect of a single high-dose simvastatin on CRP in patients with unstable angina (UA) within 48 h. We investigated whether a rapid CRP reduction can be achieved by a single 80 mg of simvastatin therapy in patients with UA given immediately on admission. Simvastatin 117-128 C-reactive protein Homo sapiens 132-135 16999946-2 2007 Limited information has been available, however, with respect to evaluating a potential effect of a single high-dose simvastatin on CRP in patients with unstable angina (UA) within 48 h. We investigated whether a rapid CRP reduction can be achieved by a single 80 mg of simvastatin therapy in patients with UA given immediately on admission. Simvastatin 117-128 C-reactive protein Homo sapiens 219-222 16999946-5 2007 RESULTS: We found that 80 mg of simvastatin induced significant reductions in serum median CRP concentrations and in mean CRP concentrations 48 h later following administration of simvastatin (25.4% and 32.7%, p<0.001, respectively). Simvastatin 32-43 C-reactive protein Homo sapiens 91-94 16999946-5 2007 RESULTS: We found that 80 mg of simvastatin induced significant reductions in serum median CRP concentrations and in mean CRP concentrations 48 h later following administration of simvastatin (25.4% and 32.7%, p<0.001, respectively). Simvastatin 32-43 C-reactive protein Homo sapiens 122-125 16999946-6 2007 CONCLUSIONS: A single high-dose simvastatin, given in the early time on admission, is an effective therapy for controlling inflammatory response in patients with UA, and the benefit to the vascular endothelium might occur quickly by reduction of CRP concentrations in this high-risk subgroup. Simvastatin 32-43 C-reactive protein Homo sapiens 246-249 17239709-10 2007 At 12 weeks, pioglitazone and simvastatin monotherapies significantly reduced hs-CRP (3.64 +/- 2.42 mg/l to 2.48 +/- 1.77 mg/l and 3.26 +/- 2.02 mg/l to 2.81 +/- 2.11 mg/l) and the combination regimen had an additive effect (from 3.49 +/- 1.97 mg/l to 2.06 +/- 1.42 mg/l, p < 0.001). Simvastatin 30-41 C-reactive protein Homo sapiens 81-84 17261959-7 2007 The effect of CRP on VCAM-1 expression in HUVECs and supernatant levels of MCP-1 and IL-6 were significantly suppressed by 25 micromol/L simvastatin with stepwise increased suppression as simvastatin dose increased to 50, 75, and 100 micromol/L (all P < 0.0001). Simvastatin 137-148 C-reactive protein Homo sapiens 14-17 17261959-7 2007 The effect of CRP on VCAM-1 expression in HUVECs and supernatant levels of MCP-1 and IL-6 were significantly suppressed by 25 micromol/L simvastatin with stepwise increased suppression as simvastatin dose increased to 50, 75, and 100 micromol/L (all P < 0.0001). Simvastatin 188-199 C-reactive protein Homo sapiens 14-17 17145229-1 2006 The aim of this study was to investigate the time course of C-reactive protein (CRP) reduction with simvastatin in patients with type 2 diabetes mellitus. Simvastatin 100-111 C-reactive protein Homo sapiens 60-78 17145229-1 2006 The aim of this study was to investigate the time course of C-reactive protein (CRP) reduction with simvastatin in patients with type 2 diabetes mellitus. Simvastatin 100-111 C-reactive protein Homo sapiens 80-83 17145229-7 2006 After simvastatin administration, there was a significant reduction in levels of log(hs-CRP) (p = 0.001). Simvastatin 6-17 C-reactive protein Homo sapiens 88-91 17145229-8 2006 This effect of simvastatin was seen by day 7 (p = 0.008), with maximal reduction seen at day 14 (p = 0.004; hs-CRP in original units 3.1 +/- 0.5 mg/L with simvastatin and 4.1 +/- 0.6 mg/L with placebo). Simvastatin 15-26 C-reactive protein Homo sapiens 111-114 17145229-10 2006 By day 28 with simvastatin, hs-CRP had returned to near baseline levels. Simvastatin 15-26 C-reactive protein Homo sapiens 31-34 17145229-11 2006 In conclusion, in patients with type 2 diabetes mellitus, simvastatin reduced hs-CRP within 7 days. Simvastatin 58-69 C-reactive protein Homo sapiens 81-84 17165637-8 2006 Ezetimibe/ simvastatin, 10/20 mg/d, reduced high-sensitivity C-reactive protein and triglyceride levels significantly more than atorvastatin, 10 mg/d (P = .02), with comparable reductions at other doses. Simvastatin 11-22 C-reactive protein Homo sapiens 61-79 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Simvastatin 35-46 C-reactive protein Homo sapiens 72-75 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Simvastatin 35-46 C-reactive protein Homo sapiens 255-258 16054696-5 2006 Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1beta The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1beta were present with the cells. Simvastatin 35-46 C-reactive protein Homo sapiens 255-258 16858354-14 2006 CONCLUSION: Short term simvastatin use in patients with systolic heart failure due to CHD caused lowering of LDLCH and CRP however this was not associated with changes of left ventricular EF different from those in control group. Simvastatin 23-34 C-reactive protein Homo sapiens 119-122 16265685-5 2005 RESULTS: Simvastatin treatment significantly decreased serum CRP and TNF-a [from 14 +/- 6 to 7 +/- 3 mg/l (p = 0.025) and 30 +/- 5 to 16 +/- 4 pg/ml (p = 0.012), respectively], while quinapril had no significant changes in these 2 measures. Simvastatin 9-20 C-reactive protein Homo sapiens 61-64 15994744-13 2005 The CRP level of the group also decreased with Simvastatin but it did not reach significance (P = 0.057). Simvastatin 47-58 C-reactive protein Homo sapiens 4-7 16281491-8 2005 Only maximal dose simvastatin produced a significant reduction of C-reactive protein (CRP) to the disease day 14. Simvastatin 18-29 C-reactive protein Homo sapiens 66-84 16113803-3 2005 Simvastatin, but not fenofibrate, lowered C-reactive protein (CRP) by 32% on day 3 (p<0.001), while both drugs reduced CRP significantly on day 28. Simvastatin 0-11 C-reactive protein Homo sapiens 42-60 16113803-3 2005 Simvastatin, but not fenofibrate, lowered C-reactive protein (CRP) by 32% on day 3 (p<0.001), while both drugs reduced CRP significantly on day 28. Simvastatin 0-11 C-reactive protein Homo sapiens 62-65 15883229-9 2005 When compared with simvastatin or ramipril alone, combined therapy significantly reduced high-sensitivity C-reactive protein levels (P=0.004 by ANOVA). Simvastatin 19-30 C-reactive protein Homo sapiens 106-124 15777554-1 2005 OBJECTIVE: This study assessed the effect of coadministration of ezetimibe and simvastatin on high sensitivity C-reactive protein (hs-CRP) in a large subject cohort (N=1089). Simvastatin 79-90 C-reactive protein Homo sapiens 111-129 16281491-8 2005 Only maximal dose simvastatin produced a significant reduction of C-reactive protein (CRP) to the disease day 14. Simvastatin 18-29 C-reactive protein Homo sapiens 86-89 16281491-10 2005 CONCLUSION: Use of simvastatin in ACS patients, initially normal level of LDLP cholesterol and elevated level of CRP produced a dose-dependent effect, alleviated inflammation and improved the disease course. Simvastatin 19-30 C-reactive protein Homo sapiens 113-116 12826933-0 2003 Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Simvastatin 0-11 C-reactive protein Homo sapiens 76-94 15184351-7 2004 In study II ramipril alone did not significantly change lipoproteins and C-reactive protein levels, however, simvastatin combined with ramipril significantly changed lipoproteins and C-reactive protein levels more than ramipril alone (P<0.001 and P=0.048 by ANOVA, respectively). Simvastatin 109-120 C-reactive protein Homo sapiens 183-201 15250255-1 2004 OBJECTIVE: To evaluate the effects of simvastatin combined with omega-3 fatty acids on high sensitive C-reactive protein (HsCRP), lipidemia, and fibrinolysis in coronary heart disease (CHD) and CHD risk equivalent patients with mixed dyslipidemia. Simvastatin 38-49 C-reactive protein Homo sapiens 102-120 15193818-3 2004 RESULTS: Compared with diet alone, simvastatin significantly improved the percent flow-mediated dilator response to hyperemia and lowered plasma levels of tumor necrosis factor (TNF)-alpha, intercellular adhesion molecule type-1 (ICAM-1), serum levels of CRP, and fibrinogen (P<0.001, P<0.001, P=0.035, P<0.001 and P=0.014, respectively). Simvastatin 35-46 C-reactive protein Homo sapiens 255-258 15193818-5 2004 Further, we observed that patients with the highest pretreatment TNF-alpha, ICAM-1, and CRP levels showed the greatest extent of reductions on simvastatin. Simvastatin 143-154 C-reactive protein Homo sapiens 88-91 14715352-0 2004 Effect of simvastatin on serum C-reactive protein during hormone replacement therapy. Simvastatin 10-21 C-reactive protein Homo sapiens 31-49 15050096-6 2004 In our recent study, the results demonstrate that monocytes exhibit an enhanced production of interleukin-6 (IL-6) in response to CRP, and this response is significantly inhibited by simvastatin in a dose-dependent manner. Simvastatin 183-194 C-reactive protein Homo sapiens 130-133 15050096-10 2004 Our clinical investigation suggested that treatment with a single high-dose or a short-term common dose of simvastatin could rapidly reduce CRP level. Simvastatin 107-118 C-reactive protein Homo sapiens 140-143 15540478-9 2004 Researchers in the CURVES study found a significant reduction in CRP levels with pravastatin, simvastatin, and atorvastatin compared with baseline (p < 0.025). Simvastatin 94-105 C-reactive protein Homo sapiens 65-68 14504184-7 2003 Simvastatin, but not aspirin treatment, significantly lowered CRP levels (P<0.05). Simvastatin 0-11 C-reactive protein Homo sapiens 62-65 14612213-5 2003 Both fenofibrate and simvastatin markedly reduced plasma levels of high-sensitivity CRP, IL-1 beta, and sCD40L, and improved endothelium-dependent FMD without mutual differences. Simvastatin 21-32 C-reactive protein Homo sapiens 84-87 14579918-0 2003 Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Simvastatin 17-28 C-reactive protein Homo sapiens 50-68 14579918-3 2003 HYPOTHESIS: The study was undertaken to investigate whether a rapid LDL cholesterol and CRP reduction can be achieved by 2-week simvastatin therapy using a common lipid-lowering protocol in patients with hypercholesterolemia. Simvastatin 128-139 C-reactive protein Homo sapiens 88-91 14579918-10 2003 In addition, both doses of simvastatin induced significant reductions in mean CRP levels on Day 14 (22.3 and 23.1%) in a non dose-dependent manner (p < 0.001, respectively. Simvastatin 27-38 C-reactive protein Homo sapiens 78-81 14579918-11 2003 CONCLUSIONS: Our data suggest that a common daily dose of simvastatin, especially 40 mg, is an effective 2-week therapy for patients with hypercholesterolemia, and benefit to the vascular endothelium can be derived quickly by reduction of CRP levels. Simvastatin 58-69 C-reactive protein Homo sapiens 239-242 12826933-5 2003 Also 10-8-10-6 mol/l simvastatin was coincubated with cells in the presence of CRP and LPS. Simvastatin 21-32 C-reactive protein Homo sapiens 79-82 12826933-11 2003 CONCLUSIONS: CRP and LPS could induce IL-6 release in human monocytes and simvastatin could inhibit this response in a dose-dependent manner, which may provide an insight into the mechanisms of anti-inflammatory or anti-atherosclerotic actions of simvastatin. Simvastatin 74-85 C-reactive protein Homo sapiens 13-16 12826933-11 2003 CONCLUSIONS: CRP and LPS could induce IL-6 release in human monocytes and simvastatin could inhibit this response in a dose-dependent manner, which may provide an insight into the mechanisms of anti-inflammatory or anti-atherosclerotic actions of simvastatin. Simvastatin 247-258 C-reactive protein Homo sapiens 13-16 12398959-0 2002 Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. Simvastatin 11-22 C-reactive protein Homo sapiens 26-44 12477621-0 2002 Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. Simvastatin 0-11 C-reactive protein Homo sapiens 61-79 12375804-5 2002 At a 4-month control, simvastatin reduced CRP levels (p = 0.009) while placebo did not (p = NS). Simvastatin 22-33 C-reactive protein Homo sapiens 42-45 12398959-7 2002 Treatment with simvastatin 20, 40, and 80 mg led to significant reductions in CRP plasma levels versus placebo (p <0.05). Simvastatin 15-26 C-reactive protein Homo sapiens 78-81 12398959-10 2002 In summary, simvastatin significantly reduced CRP in patients with mixed hyperlipidemia and hypertriglyceridemia. Simvastatin 12-23 C-reactive protein Homo sapiens 46-49 12375804-8 2002 Simvastatin treatment reduces CRP levels, but without affecting the increased risk conferred by higher CRP levels at baseline. Simvastatin 0-11 C-reactive protein Homo sapiens 30-33 12046033-7 2002 In the treatment group, simvastatin administration for 8 weeks significantly reduced total cholesterol levels from 232 +/- 25 to 165 +/- 39 mg/dL (P < 0.001) and hs-CRP levels from a median of 0.23 mg/dL (range, 0.05 to 1.63 mg/dL) to 0.12 mg/dL (range, <0.006 to 1.45 mg/dL; P < 0.01), whereas it increased serum albumin levels from 3.4 +/- 0.3 to 3.6 +/- 0.4 g/dL (P < 0.001). Simvastatin 24-35 C-reactive protein Homo sapiens 168-171 12234946-0 2002 Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Simvastatin 0-11 C-reactive protein Homo sapiens 19-37 12234946-2 2002 The purpose of this study was to determine the rate at which highly sensitive C-reactive protein (hsCRP) levels change after initiation of simvastatin and whether this occurs independently of the change in LDL cholesterol. Simvastatin 139-150 C-reactive protein Homo sapiens 78-96 11835933-0 2002 Effects of simvastatin (40 and 80 mg) on highly sensitive C-reactive protein in patients with combined hyperlipidemia. Simvastatin 11-22 C-reactive protein Homo sapiens 58-76 11927515-4 2002 CEEs increased median CRP levels from 0.27 to 0.46 mg/dL, simvastatin decreased CRP from 0.29 to 0.28 mg/dL, and the therapies combined increased CRP from 0.28 to 0.36 mg/dL (all P< or =0.02 versus respective baseline values). Simvastatin 58-69 C-reactive protein Homo sapiens 80-83 11927515-4 2002 CEEs increased median CRP levels from 0.27 to 0.46 mg/dL, simvastatin decreased CRP from 0.29 to 0.28 mg/dL, and the therapies combined increased CRP from 0.28 to 0.36 mg/dL (all P< or =0.02 versus respective baseline values). Simvastatin 58-69 C-reactive protein Homo sapiens 80-83 11927515-5 2002 Post hoc testing showed that the 29% increase in CRP on the combination of CEEs with simvastatin was significantly less than the 70% increase in CRP on CEEs alone (P<0.05). Simvastatin 85-96 C-reactive protein Homo sapiens 49-52 11472751-3 2001 The aim of this study was to evaluate the effect of one year of simvastatin treatment on serum levels of CRP and to assess the influence of risk factors for CVD on CRP concentrations in patients with FH. Simvastatin 64-75 C-reactive protein Homo sapiens 105-108 11182189-2 2001 The aim of the study was to assess the influence of simvastatin and aspirin on serum levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in hypercholesterolemic subjects. Simvastatin 52-63 C-reactive protein Homo sapiens 95-113 11306519-5 2001 hs-CRP levels were significantly decreased after treatment with all 3 statins compared with baseline (median values: baseline, 2.6 mg/L; atorvastatin, 1.7 mg/L; simvastatin, 1.7 mg/L; and pravastatin, 1.9 mg/L; P<0.025). Simvastatin 161-172 C-reactive protein Homo sapiens 3-6 11306519-9 2001 CONCLUSIONS: Pravastatin, simvastatin, and atorvastatin significantly decreased levels of hs-CRP. Simvastatin 26-37 C-reactive protein Homo sapiens 93-96 11382718-7 2001 The effect of CRP on MCP-1 induction was not influenced by aspirin (at concentrations up to 1 mmol/L), but it was significantly inhibited by 5 micromol/L simvastatin. Simvastatin 154-165 C-reactive protein Homo sapiens 14-17 11382718-9 2001 CONCLUSIONS: These results further strengthen the role of CRP in the pathogenesis of vascular inflammation and, likely, atherosclerosis and provide a crucial insight into a novel mechanism of action of anti-atherosclerosis drugs such as simvastatin and fenofibrate. Simvastatin 237-248 C-reactive protein Homo sapiens 58-61 11182189-7 2001 CONCLUSIONS: In men with hypercholesterolemia simvastatin treatment lowers serum levels of CRP and proinflammatory cytokines. Simvastatin 46-57 C-reactive protein Homo sapiens 91-94 32747455-9 2020 Tissue cholesterol, CRP levels and RAM 11 were significantly lower in simvastatin and ezetimibe rabbit groups compared with cholesterol diet alone. Simvastatin 70-81 C-reactive protein Homo sapiens 20-23 33224343-5 2020 Among statins, rosuvastatin had the strongest interaction with CRP (pKi = 16.14), followed by fluvastatin (pKi = 15.58), pitavastatin (pKi = 15.26), atorvastatin (pKi = 14.68), pravastatin (pKi = 13.95), simvastatin (pKi = 7.98) and lovastatin (pKi = 7.10). Simvastatin 204-215 C-reactive protein Homo sapiens 63-66 31734364-9 2020 However, endocan and simvastatin combination treatment could suppress NO, ROS production and iNOS, CRP activation. Simvastatin 21-32 C-reactive protein Homo sapiens 99-102 31935793-6 2020 Statins reverted the increased levels of Lp-PLA2 and CRP. Simvastatin 0-7 C-reactive protein Homo sapiens 53-56 31955966-3 2020 This study systematically reviewed and summarized earlier findings from randomized clinical trials about the effects of statins on serum concentrations of C-reactive protein (CRP) and interleukin (IL)-6 in patients with abnormal glucose homeostasis. Simvastatin 120-127 C-reactive protein Homo sapiens 155-173 31955966-3 2020 This study systematically reviewed and summarized earlier findings from randomized clinical trials about the effects of statins on serum concentrations of C-reactive protein (CRP) and interleukin (IL)-6 in patients with abnormal glucose homeostasis. Simvastatin 120-127 C-reactive protein Homo sapiens 175-178 31955966-5 2020 RCTs were included if they compared the effects of statins on serum concentrations of CRP and IL-6 in adults with abnormal glucose homeostasis. Simvastatin 51-58 C-reactive protein Homo sapiens 86-89 31955966-11 2020 Pooling 6 effect sizes from 5 studies revealed a significantly reduced serum concentration of CRP after simvastatin therapy (WMD, -0.66; 95% CI, -0.79 to -0.54; I2 = 97.6%). Simvastatin 104-115 C-reactive protein Homo sapiens 94-97 31955966-12 2020 IMPLICATIONS: The administration of atorvastatin or simvastatin in patients with abnormal glucose hemostasis was associated with a reduced serum CRP concentration. Simvastatin 52-63 C-reactive protein Homo sapiens 145-148 31228727-9 2019 Pooling 5 effect sizes from 2 studies, we found a significant reduction in serum concentrations of CRP following administration of Simvastatin (WMD: -0.29; 95% CI: -0.49, -0.10; I2 = 88.5%). Simvastatin 131-142 C-reactive protein Homo sapiens 99-102 28550977-1 2017 AIMS: Evaluating the short-term influence of Ezetimibe and Simvastatin Combination Therapy on LDL-C, TG and hs-CRP expression level in patients with percutaneous coronary intervention. Simvastatin 59-70 C-reactive protein Homo sapiens 111-114 32292723-9 2019 Conclusion: Ezetimibe co-administered with simvastatin (10 mg) and high-dose statin monotherapy may show similar effects in reducing LDL-C, TG, and hs-CRP levels and in increasing HDL-C levels. Simvastatin 43-54 C-reactive protein Homo sapiens 151-154 28550977-10 2017 CONCLUSIONS: Combination therapy of Ezetimibe (10mg/day) and Simvastatin (40mg/day) was more effective than mono-therapy with Simvastatin (40mg/day) on reducing LDL-C, TG and hs-CRP level in percutaneous coronary intervention patients, leading to more significant anti-inflammatory effect. Simvastatin 61-72 C-reactive protein Homo sapiens 178-181 28426854-0 2016 Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial: Erratum. Simvastatin 119-130 C-reactive protein Homo sapiens 18-36 27022048-1 2016 and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Simvastatin 157-168 C-reactive protein Homo sapiens 82-100 27022050-0 2016 Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Simvastatin 191-202 C-reactive protein Homo sapiens 116-134 27197424-11 2016 The Q192R polymorphism was associated with simvastatin effectiveness on hs-CRP and FMD. Simvastatin 43-54 C-reactive protein Homo sapiens 75-78 27511325-10 2016 The C-reactive protein concentration 48 h after trauma was significantly lower in the simvastatin group, but there was no significant difference according to the interleukin-6 level 48 h after trauma between the 2 groups. Simvastatin 86-97 C-reactive protein Homo sapiens 4-22 27213056-10 2016 Simvastatin treatment significantly increased FMD value, decreased CRP and TNF-alpha concentration. Simvastatin 0-11 C-reactive protein Homo sapiens 67-70 26280117-0 2015 Elevated Baseline C-Reactive Protein as a Predictor of Outcome After Aneurysmal Subarachnoid Hemorrhage: Data From the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) Trial. Simvastatin 119-130 C-reactive protein Homo sapiens 18-36 26602073-9 2015 In Cox multivariate analysis adjusted for age, gender, prednisolone treatment, smoking, baseline LDL cholesterol and high sensitivity C-reactive protein; simvastatin plus ezetimibe versus placebo was associated with 44% lower risk of cataract development (hazard ratio 0.56, 95% confidence interval 0.33 to 0.96, p = 0.034). Simvastatin 154-165 C-reactive protein Homo sapiens 134-152 26330412-0 2015 Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Simvastatin 152-163 C-reactive protein Homo sapiens 77-95 26032258-9 2015 Strong positive correlations between serum angiostatin level versus concentrations of TC, LDL-C, and C-RP were demonstrated before onset of the study (r = 0.48311, 0.6252, and 0.653, respectively) and after simvastatin therapy (r = 0.67752, 0.6485, and 0.8244, respectively). Simvastatin 207-218 C-reactive protein Homo sapiens 101-105 25149995-6 2014 Apart from decreasing plasma total cholesterol, LDL cholesterol and apolipoprotein B-100 levels, simvastatin reduced plasma levels of FFA, leptin and TNF-alpha, as well as increased plasma levels of adiponectin, which was accompanied by a reduction in plasma CRP. Simvastatin 97-108 C-reactive protein Homo sapiens 259-262 26032258-7 2015 KEY FINDINGS: Simvastatin therapy improved the main parameters of lipid metabolism, including statistically significant (P < 0.05) reductions in TC (by 46%) and LDL-C (by 42%), and decreased inflammatory marker C-RP (by 32%), as compared with the baseline. Simvastatin 14-25 C-reactive protein Homo sapiens 214-218 25685360-1 2015 AIMS: To assess the prognostic importance of high-sensitive C reactive protein (hsCRP) in patients with mild to moderate aortic valve stenosis during placebo or simvastatin/ezetimibe treatment in Simvastatin and Ezetimibe in Aortic Stenosis (SEAS). Simvastatin 161-172 C-reactive protein Homo sapiens 60-78 25685360-1 2015 AIMS: To assess the prognostic importance of high-sensitive C reactive protein (hsCRP) in patients with mild to moderate aortic valve stenosis during placebo or simvastatin/ezetimibe treatment in Simvastatin and Ezetimibe in Aortic Stenosis (SEAS). Simvastatin 196-207 C-reactive protein Homo sapiens 60-78